The Scientific Registry of Transplant Recipients (SRTR) serves to collect data on organ transplants performed in the United States. Although the infectious diseases data are limited and include mostly pretransplant serologies and other nonspecific infection-related outcomes, this multicenter data collection allows for insightful national data and the ability to monitor trends over time. We reviewed the published concise reports for each organ type in SRTR reports containing data from 2005 to 2014, and summarized our findings with respect to cytomegalovirus (CMV), Epstein-Barr virus, posttransplant lymphoproliferative disorder (PTLD), hepatitis B virus (HBV), hepatitis C virus (HCV), HIV, general infection, and prophylaxis. Our review highlights a few developments. While rates of donor-recipient CMV serology combinations remain fairly constant over time, there are generally more seronegative donors and recipients among living donor transplants. There has been a reduction in PTLD for pediatric transplant recipients. There has also been a slight reduction in anti-HBV core antibodypositive donor organs and stable reporting of HCV-positive donor organs and HIV-positive recipients.
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Introduction
Infectious diseases issues significantly influence transplant morbidity, mortality, and outcomes, yet multicenter data on incidence, risks, and prevention of infection in the transplant setting are often not readily available. The Scientific Registry of Transplant Recipients (SRTR) is managed by The Chronic Disease Research Group of the Minneapolis Medical Research Foundation under U.S. federal contract/funding and with oversight from the Health Resources and Services Administration. It evolved from the United Network of Organ Sharing (UNOS) Scientific Renal Transplant Registry. Information is collected using electronic data-collection forms from local transplant centers using the Transplant Information Electronic Data Interchange (TIEDI â ) system, which was established by UNOS (1) . In general, limited infectious disease data are collected, primarily including pretransplant serologies and other nonspecific infection related outcomes. More-detailed information such as rates and outcomes of various infections or the use of increased risk donors is not collected or included in these reports.
The goal of both SRTR and the Organ Procurement and Transplantation Network (OPTN) is "to inform transplant programs, organ procurement organizations, policy makers, transplant professionals, transplant recipients, organ donors and donor families, and the general public about the current state of solid organ transplantation (SOT) in the U.S. SRTR also facilitates transplant research by providing access to data for qualified researchers interested in studying various aspects of SOT" (2) . The SRTR database thus serves as one of the largest repositories of SOT clinical data, which can be tracked over time.
In this summary, we review data related to infectious diseases presented in the published annual reports of SRTR. This summary is intended as an overview rather than as an analysis of primary data. Screening, prevention, management, and diagnosis of SOT-related infections have undergone transformative change in the past decade, and we summarize and highlight findings and trends related to infectious diseases found within the published SRTR reports.
Methods
A review of recently published SRTR Annual Data Report 2010-2014 reports, containing data from 2005 to 2014 (and earlier data, when available), was performed for each organ type. Before this period, the reports were published in a different format, making comparisons difficult. We reviewed the aggregate data available in the reports and not primary individual-level data. The majority of information in the reports is available as percentages with minimal raw numbers. In some instances, a significant proportion of data (e.g. up to 10% of serology for donor or recipient) was reported as unknown. Screening tests for infectious diseases reported in the SRTR reports included serological testing for cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. Outcomes in SRTR reports were provided for adult and pediatric posttransplant lymphoproliferative disorder (PTLD) for all organ types. Overall infection outcomes were shown for heart and lung recipients only. Data in the reports were not comprehensive for all time periods evaluated. In addition, within the SRTR reports, data linked from SRTR to IMS Health pharmacy claims showed that some antimicrobials were included among the top 15 medications in the first posttransplantation year for transplantations performed in 2009 and 2010. Detailed collection methods for the SRTR repository can be found elsewhere (1). There were nearly double the number of D À R À pairs among the living donor kidney and liver transplant recipients compared with the deceased donor pairs (23.8% vs. 12.6% for kidney and 27.3% and 11.5% for liver). . Data on serologic pairs in prior years were not previously published. Again, the decrease in CMV risk among recipients of living donor kidneys may enhance transplantation outcomes.
Results

Cytomegalovirus
EBV and PTLD NHANES data show that the seroprevalence of EBV in the United States is 83% by age 19 years (8) . In SOT recipients, the rates of EBV mismatch ranged from 4.6% to 12.5% (Tables 2 and 3 ). Rates of serologic matching were similar between organs in the time periods 2005-2009 and 2010-2014. Pediatric recipients were more commonly EBV mismatches than were adult recipients for all organ types.
The overall 5-year PTLD rates in adults ranged from 0.6% to 9.0% (Table 4 ). SRTR data show that intestinal (~9%) and lung (~2%) transplantations had the overall highest PTLD rates, which were dependent on transplant type but also on EBV serology (seronegative recipients had the greatest risk). During 2005-2010, adult PTLD rates appeared to be stable. For pediatric transplant recipients, PTLD rates from 2002 to 2012 ranged from 2% to 9%, with the lowest risk in kidney transplant recipients (Table 5 ). There appears to be a substantial decline in PTLD rates reported in the 2002-2012 cohort compared with the 2000-2009 cohort for nearly all transplant types. Multiple factors, including changes in immunosuppression, increased monitoring of EBV viral loads with preemptive reduction in immunosuppression, and the use of antivirals, may explain the reduction in PTLD (9).
The SRTR database has been used by several investigators to study the rates of PTLD. Using the SRTR Categories do not sum to 100% due to unknown EBV serology results in the donor or the recipient. (11) . SRTR data appear to be comparable to PTLD rates for kidney recipients in the French transplant registry. However, when PTLD diagnosis was compared between SRTR and Medicare claims data, the incidence rate was twofold greater in Medicare claims, demonstrating some inconsistency between these large databases (12).
HBV, HCV, and HIV infections Donor and recipient serologic (but not nucleic acid testing) data regarding HBV, HCV, and HIV infection are reported in detail for liver and kidney recipients (Tables 6  and 7 ). Approximately 5% of deceased liver donors were anti-hepatitis B core antibody seropositive (anti-HBc + ). In the past 10 years, however, there has been a slight reduction in the frequency of anti-HBc + deceased donors Because the use of these organs is accepted and endorsed by guidelines (13), the reduction may be related to decreased prevalence (as has been noted in blood donors) rather than a reluctance to use such organs. This hypothesis is supported by the gradual decline in anti-HBc + deceased kidney donors as well Because HCV transmission has been rarely reported (16, 17) in the era of nucleic acid testing (NAT), this may be due to error in data entry. It is also possible that that the HCV + donors were HCV NAT negative and the recipient transplant center was aware of this information when the organs were accepted (or that there was error in data entry).
Since 2007, 0.5-0.6% of deceased donor liver transplant recipients and 0.7% of deceased donor kidney transplant recipients were HIV seropositive (HIV + ). Since 2009, 0.3% of living donor liver transplant recipients and 0.3-0.4% of living donor kidney transplant recipients were HIV + . These findings are consistent with the reported success in performing kidney and liver transplantation in HIV + patients from both multicenter prospective clinical trials (18) (19) (20) and queries of SRTR data (21) (22) (23) , and these trends are likely to either remain stable or increase in the future.
One notable observation in the SRTR data is the high frequency of unknown, incomplete, or pending HBV and HIV status among living liver or kidney donors, although this has consistently improved during the past 10 years (Tables 6 and 7) . Because HBV and HIV status is considered essential information in the evaluation of living donors, it is likely these tests were in fact performed but the results were not entered into the SRTR. 
General infection
The mention of "overall infection" rates in SRTR reports is limited across different organ transplantations and is primarily reported among heart and lung transplant recipients, where infection was an important cause of mortality during the 2008-2012 period. Approximately 3% of deaths were from infection by 5 years after adult heart transplantation. Infection was the primary cause of mortality in the first year after lung transplant for both adult and pediatric transplant recipients. Nearly 5% of adult lung transplant recipients died from infection by 1 year after transplantation, and nearly 10% died from infection by year 5. A different pattern was seen in pediatric lung transplantation, where among deceased donor pediatric lung transplant recipients, just over 5% died from infection in the first year after transplantation but, unlike with adults, this rate did not increase considerably by year 5.
Of deceased donor pediatric liver transplant recipients, 12% died within 5 years of transplantation and the leading cause of death was infection at 1 year (~1%) and 5 years (nearly 2%). (Figure 2) . From the data provided, it is not possible to know how much of the valganciclovir prescribing was for prevention, either via prophylaxis or as preemptive therapy, versus treatment of infection, nor are data available on duration of valganciclovir use.
Anti-infective use
Although valganciclovir is not approved by the Food and Drug Administration for use in liver transplant recipients, it is frequently prescribed. In 2010, 34% of liver transplant recipients filled a valganciclovir prescription, which was the lowest rate for any organ transplanted but was only 7-8% lower than the rates in heart and kidney transplant recipients. As discussed earlier, this number may be somewhat lower than the actual rate of use; for example, there was a major discrepancy elsewhere, while only 48% of the cohort were taking tacrolimus after liver transplantation according to the IMS Health data, while~90% were taking tacrolimus, per primary SRTR data (27) . In a survey published in 2008, more than half of centers were already using valganciclovir prophylaxis for at-risk liver transplant recipients (28). The first international CMV guidelines were published in April 2010 (29) , which may have influenced the use of valganciclovir. In addition, trials in kidney and lung transplant recipients demonstrating the efficacy of prolonged valganciclovir prophylaxis were published in the spring of 2010, which again may have influenced practice (30, 31) .
The overall accuracy of these numbers from the IMS Health database are questionable and seem to be low. While 42% of adult renal transplant recipients filled a prescription for valganciclovir in 2010, only 53% of the same cohort filled a prescription for tacrolimus and 54% for mycophenolate, which is much lower than the~90% reported rates for both reported elsewhere in the SRTR (32) . K i d n e y P a n c r e a s L i v e r H e a r t L u n g I n t e s Ɵ n e 
Discussion
We reviewed published SRTR reports, specifically looking at infectious diseases data and outcomes. Although the infectious diseases data presented in the reports are fairly limited, our review highlights a few interesting trends. While rates of donor-recipient CMV serology combinations remain fairly constant over time, there are generally more seronegative donors and recipients among living donor transplantations and, thus, a lower risk of CMV infection. There has been a reduction in PTLD for pediatric transplant recipients. There has also been a slight reduction in anti-HBc + donor organs. Although use the of HCV + donor organs has been stable, this is likely to increase with the advent of effective HCV treatments and some programs studying HCV D + R À . The use of HIV + donors will also increase with the implementation of the HOPE Act, allowing for transplantations between HIV seropositive donors and seropositive recipients in a research setting.
In the past decade, a number of infectious diseases guidelines have been published that may have influenced practice. These include the American Society of Transplantation infectious diseases guidelines in 2009 and 2013 (33, 34) and the international consensus guidelines on CMV (35) . Several advances have been made for CMV including evidence for the use of prolonged antiviral prophylaxis in kidney and lung transplantations (30, 31, 36) . More recently, consensus guidelines on the use of organs from HBV + donors were published (13) .
The data presented represent an aggregate view of published SRTR reports and are not a detailed analysis of original patient-level data. Therefore, statistical analysis was not possible. Having more infection-specific information entered into the SRTR database in the future would likely be useful to clinicians. Given the impact of infections on overall patient and graft survival, the SRTR would be an ideal repository to capture additional infectious diseasesspecific outcomes (i.e. CMV infection, surgical site infection, donor-derived infection). In addition to having a focus on organ-specific outcomes as it does now, a focus within the SRTR database on infectious outcomes would likely strengthen the data and allow for changes in protocols and clinical practice, enhancing transplantation outcomes. This would require the use of careful definitions of disease and outcomes as well as education of those entering data. Logistical and cost issues also need to be considered if data entry is expanded. In addition, capturing more-comprehensive pediatric data would likely be useful in managing a vulnerable population.
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